COMPARE · Data as of August 24, 2026
ANIP vs BMY
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 80.0, BMY scored 61.5 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
80
$74.17 · $1.7B
fundamentals as of
Score gap
18.5
ANIP leads
BMY
Bristol-Myers Squibb Company
61.5
$67.28 · $137.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBMY14.8x
- Fastest growthANIP+30.9%
- Strongest balance sheetANIP1.05
- Highest qualityBMY79 / 100
- Largest discount to fair valueANIP-47%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
BMY
66
Qualityreturns · margins · balance sheet
79
94
Growthrevenue & earnings expansion
57
82
Valuevaluation vs sector peers
52
ANIP is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
BMY
$173mC
FCF
$11.4bA-
+30.9%A
Rev
+3.1%C+
1.05C
D/E
2.02D
16.2xA-
P/E
14.8xA-
1.21B
PEG
2.37C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
BMY
47% below
Price vs fair valuelower is cheaper
2% below
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-2%/yr
+64%
1-yr DCF upside
+13%
+88%
5-yr DCF upside
+2%
+127%
10-yr DCF upside
-12%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
BMY
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 25% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +46% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
BMYBristol-Myers Squibb Company
Why now
Drug Manufacturers - General · market cap $137.4b. Trading near 52-week high of $68.64 — momentum setup, limited technical margin of safety. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $66.21 (implying -2% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
D/E 2.02 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and BMY diverge
On the headline score the gap is 18.5 points in favor of ANIP. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthANIP 93.8 · BMY 57.2ANIP +36.6
- ValueANIP 82.5 · BMY 51.5ANIP +31.0
- QualityANIP 66.2 · BMY 78.9BMY +12.7
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.